Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Lobby Warns Of Proposed EU-India Free Trade Agreement's Impact; Says Drug Supplies Of Developing Nations May Be In Jeopardy

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As India and the European Union draw closer to signing a comprehensive Free Trade Agreement, the Indian Pharmaceutical Alliance - an influential lobby group of leading Indian pharmaceutical companies - has appealed to the Indian government to exercise caution and abstain from giving in to EU's demands, particularly those that allegedly ask for "TRIPS plus" provisions to be incorporated in the Indian legal framework

You may also be interested in...



Headway Seen In EU-India FTA Talks, Commerce Ministry Joint Secretary Says

Disputes over EU blockades of Indian drug shipments are still on the negotiation table, says Commerce Ministry. India hopes to initiate talks with China as well.

Indian Pharma Lobby Flays India-EU Trade Talks; Debunks "TRIPS Plus" Provisions On Patent Extensions And Data Protection

MUMBAI - Hardball negotiations between Indian and European Union representatives on the signing of a free trade agreement may lead to flare ups after the Indian Pharmaceutical Alliance - a powerful industry lobby - raised strong objections on provisions related to intellectual property rights that are sought to be incorporated in the draft treaty

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel